Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR1 | P21453 | 4/20 | 0.44 |
| ▸ | S1PR4 | O95977 | 2/20 | 0.44 |
| ▸ | S1PR3 | Q99500 | 2/20 | 0.44 |
| ▸ | S1PR5 | Q9H228 | 2/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | HRH3 | Q9Y5N1 | 6/20 | 0.43 |
| ▸ | L3MBTL3 | Q96JM7 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.43 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.41 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL3833288 | 0.99 | S1PR1 (0.44) | S1PR1S1PR4S1PR3S1PR5GAA | |
| SCHEMBL2896686 | 0.88 | S1PR1 (0.38) | S1PR1S1PR4S1PR3S1PR5GAA | |
| SCHEMBL2901934 | 0.87 | LMNA (0.45) | S1PR1S1PR4S1PR3S1PR5GAA | |
| SCHEMBL2901983 | 0.83 | SPHK2 (0.37) | S1PR1S1PR4S1PR3S1PR5HRH3 | |
| SCHEMBL2902042 | 0.83 | RAB9A (0.48) | S1PR1S1PR4S1PR5GAAMEN1 | |
| SCHEMBL2901513 | 0.83 | S1PR1 (0.40) | S1PR1S1PR4S1PR3S1PR5HRH3 | |
| SCHEMBL2899233 | 0.83 | USP7 (0.41) | S1PR1S1PR4S1PR3S1PR5HRH3 | |
| SCHEMBL2901979 | 0.83 | SPHK1 (0.38) | S1PR1S1PR4S1PR3S1PR5HRH3 | |
| SCHEMBL2902078 | 0.82 | S1PR1 (0.45) | S1PR1S1PR4S1PR3S1PR5GAA | |
| SCHEMBL2900885 | 0.82 | MAPK1 (0.46) | S1PR1S1PR4S1PR3S1PR5GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1585515-B1 | PIPERIDINE AND PYRROLIDINE DERIVATIVES AS ANTAGONISTS OF HISTAMINE H3 RECEPTOR | HIGH POINT PHARMACEUTICALS LLC (US) | 2009-09-16 | — | — | EP | claimed |
| US-7799924-B2 | 1-Cyclopentyl-4-{2-[5-(4-methanesulfonylphenyl)[1,2,4]oxadiazol-3-yl]ethyl}piperidine; histamine-H3 receptor antagonist or inverse agonist; nervous system, cardiovascular , respiratory system, gastrointestinal system and endocrinological system disorders | HIGH POINT PHARMACEUTICALS, LLC (US) | 2010-09-21 | — | — | US | disclosed |
| US-7799924-B2 | 1-Cyclopentyl-4-{2-[5-(4-methanesulfonylphenyl)[1,2,4]oxadiazol-3-yl]ethyl}piperidine; histamine-H3 receptor antagonist or inverse agonist; nervous system, cardiovascular , respiratory system, gastrointestinal system and endocrinological system disorders | HIGH POINT PHARMACEUTICALS, LLC (US) | 2010-09-21 | — | — | US | disclosed |
| US-7799924-B2 | 1-Cyclopentyl-4-{2-[5-(4-methanesulfonylphenyl)[1,2,4]oxadiazol-3-yl]ethyl}piperidine; histamine-H3 receptor antagonist or inverse agonist; nervous system, cardiovascular , respiratory system, gastrointestinal system and endocrinological system disorders | HIGH POINT PHARMACEUTICALS, LLC (US) | 2010-09-21 | — | — | US | disclosed |
| EP-1585515-B1 | PIPERIDINE AND PYRROLIDINE DERIVATIVES AS ANTAGONISTS OF HISTAMINE H3 RECEPTOR | HIGH POINT PHARMACEUTICALS LLC (US) | 2009-09-16 | — | — | EP | disclosed |
| EP-1585515-B1 | PIPERIDINE AND PYRROLIDINE DERIVATIVES AS ANTAGONISTS OF HISTAMINE H3 RECEPTOR | HIGH POINT PHARMACEUTICALS LLC (US) | 2009-09-16 | — | — | EP | disclosed |
| US-20080113995-A1 | 1-Cyclopentyl-4-{2-[5-(4-methanesulfonylphenyl)[1,2,4]oxadiazol-3-yl]ethyl}piperidine; histamine-H3 receptor antagonist or inverse agonist; nervous system, cardiovascular , respiratory system, gastrointestinal system and endocrinological system disorders | NOVO NORDISK A/S (DK) | 2008-05-15 | — | — | US | disclosed |
| US-20080113995-A1 | 1-Cyclopentyl-4-{2-[5-(4-methanesulfonylphenyl)[1,2,4]oxadiazol-3-yl]ethyl}piperidine; histamine-H3 receptor antagonist or inverse agonist; nervous system, cardiovascular , respiratory system, gastrointestinal system and endocrinological system disorders | NOVO NORDISK A/S (DK) | 2008-05-15 | — | — | US | disclosed |
| US-20080113995-A1 | 1-Cyclopentyl-4-{2-[5-(4-methanesulfonylphenyl)[1,2,4]oxadiazol-3-yl]ethyl}piperidine; histamine-H3 receptor antagonist or inverse agonist; nervous system, cardiovascular , respiratory system, gastrointestinal system and endocrinological system disorders | NOVO NORDISK A/S (DK) | 2008-05-15 | — | — | US | disclosed |
| US-7332508-B2 | heterocyclic amines such as 1-Cyclopentyl-4-{2-[5-(4-methanesulfonylphenyl)[1,2,4]oxadiazol-3-yl]ethyl}piperidine and salts, used as histamine-H3 receptor antagonists for treatment of nervous system, cardiovascular , respiratory system, gastrointestinal system and endocrinological system disorders | NOVO NORDISK A/S (DK) | 2008-02-19 | — | — | US | disclosed |
| US-7332508-B2 | heterocyclic amines such as 1-Cyclopentyl-4-{2-[5-(4-methanesulfonylphenyl)[1,2,4]oxadiazol-3-yl]ethyl}piperidine and salts, used as histamine-H3 receptor antagonists for treatment of nervous system, cardiovascular , respiratory system, gastrointestinal system and endocrinological system disorders | NOVO NORDISK A/S (DK) | 2008-02-19 | — | — | US | disclosed |
| US-7332508-B2 | heterocyclic amines such as 1-Cyclopentyl-4-{2-[5-(4-methanesulfonylphenyl)[1,2,4]oxadiazol-3-yl]ethyl}piperidine and salts, used as histamine-H3 receptor antagonists for treatment of nervous system, cardiovascular , respiratory system, gastrointestinal system and endocrinological system disorders | NOVO NORDISK A/S (DK) | 2008-02-19 | — | — | US | disclosed |
| EP-1585515-A2 | PIPERIDINE AND PYRROLIDINE DERIVATIVES AS ANTAGONISTS OF HISTAMINE H3 RECEPTOR | NOVO NORDISK A/S (DK) | 2005-10-19 | — | — | EP | disclosed |
| US-20050107434-A1 | heterocyclic amines such as 1-Cyclopentyl-4-{2-[5-(4-methanesulfonylphenyl)[1,2,4]oxadiazol-3-yl]ethyl}piperidine and salts, used as histamine-H3 receptor antagonists for treatment of nervous system, cardiovascular , respiratory system, gastrointestinal system and endocrinological system disorders | VTVX HOLDINGS II LLC | 2005-05-19 | — | — | US | disclosed |
| WO-2004054973-A2 | PIPERIDINE AND PYRROLIDINE DERIVATIVES AS ANTAGONISTS OF HISTAMINE H3 RECEPTOR | NOVO NORDISK A/S (DK) | 2004-07-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080113995-A1 | 1-Cyclopentyl-4-{2-[5-(4-methanesulfonylphenyl)[1,2,4]oxadiazol-3-yl]ethyl}piperidine; histamine-H3 receptor antagonist or inverse agonist; nervous system, cardiovascular , respiratory system, gastrointestinal system and endocrinological system disorders | HRH3, HRH4, HRH2 | S1PR1 234/4885S1PR4 229/4885S1PR3 151/4885 |
| US-20050107434-A1 | heterocyclic amines such as 1-Cyclopentyl-4-{2-[5-(4-methanesulfonylphenyl)[1,2,4]oxadiazol-3-yl]ethyl}piperidine and salts, used as histamine-H3 receptor antagonists for treatment of nervous system, cardiovascular , respiratory system, gastrointestinal system and endocrinological system disorders | HRH4, HRH3, HRH2 | S1PR1 332/4885S1PR4 309/4885S1PR3 233/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.